• NuWays reiterated a BUY rating on Aiforia, citing a completed € 6.4 million directed share issue that reduced near-term funding risk.
• The placement issued 3,600,000 shares at € 1.77, lifting the share count to 37,390,000 and implying roughly 9.6% post-money dilution.
• NuWays now expects liquidity to extend through Q3 2027, with a non-binding European Investment Bank term sheet offering up to € 20 million venture debt.
• The firm cut its 12-month target price to € 3.6 from € 3.8 to reflect dilution, leaving its valuation framework otherwise unchanged.
• NuWays flagged Aug. 28 H1 results as the next catalyst, projecting very strong growth with clinical revenue doubling year over year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aiforia Technologies Oyj published the original content used to generate this news brief via EQS News (Ref. ID: rc_26072) on June 29, 2026, and is solely responsible for the information contained therein.